The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Anticipated Rise In Market Value Of The Next Generation Immunotherapies Market During The Forecast Period?
The next generation immunotherapies market size has expanded quickly in recent years. It is forecast to increase from $150.12 billion in 2025 to $168.33 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 12.1%. The expansion observed historically can be attributed to factors such as increasing global cancer prevalence, the initial accomplishments of immune checkpoint inhibitors, augmented investments in oncology research and development, regulatory authorizations of monoclonal antibodies, and heightened awareness of immuno-oncology therapies.
The next generation immunotherapies market size is anticipated to undergo significant expansion in the coming years, projected to reach $262.82 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.8%. This growth during the forecast period is attributable to breakthroughs in next-generation antibody engineering, the expansion of applications beyond oncology, an increasing number of approvals for ADC-based therapies, the advancement of biomarker-driven treatment selection, and a growing demand for durable and long-lasting therapies. Prominent trends for the forecast period include the broader adoption of combination immunotherapy regimens, the rise of personalized cancer vaccines, the increasing use of bispecific antibodies, a heightened focus on reducing immune-related adverse events, and accelerated clinical trial activity targeting solid tumors.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21231&type=smp
What Key Factors Are Shaping The Next Generation Immunotherapies Market Landscape?
The increasing occurrence of cancer is projected to stimulate the growth of the next-generation immunotherapies market moving forward. Cancer refers to a collection of illnesses defined by the uncontrolled proliferation and dispersion of atypical cells within the body. The widespread presence of cancer stems from factors such as an aging global populace, shifts in lifestyle, environmental exposures, and enhanced detection methodologies. Next-generation immunotherapies offer sophisticated, precise treatments that boost the body’s immune reaction against cancer, leading to superior efficacy, endurance, and tailored care. For example, in July 2024, projections released by Cancer Research UK, a UK-based cancer charity, indicated that cancer incidence rates in the United Kingdom are expected to climb for most types between 2023-2025 and 2038-2040, with increases ranging from less than 1% for breast cancer to 50% for eye cancer, while a smaller subset of cancers is anticipated to decline, seeing reductions from 2% for lung cancer to 27% for mesothelioma. Hence, the rising prevalence of cancer is fostering the expansion of the next-generation immunotherapies market.
What Segment Categories Shape The Next Generation Immunotherapies Market Segment Landscape?
The next generation immunotherapies market covered in this report is segmented –
1) By Drug Class: Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Angiotensin-Converting Enzyme (ACE) Inhibitors, Immune Checkpoint Inhibitors
2) By Route Of Administration: Intravenous, Parenteral, Intratumoral, Subcutaneous, Oral
3) By Distribution Channel: Hospital Pharmacies, Clinical Pharmacies, Other Distribution Channels
Subsegments:
1) By Monoclonal Antibodies: Anti-PD-1 Antibodies, Anti-PD-L1 Antibodies, Anti-CTLA-4 Antibodies, Anti-CD20 Antibodies
2) By Antibody-Drug Conjugates (ADCs): HER2-Targeted ADCs, CD30-Targeted ADCs, CD19-Targeted ADCs
3) By Angiotensin-Converting Enzyme (ACE) Inhibitors: ACE Inhibitors For Cancer Therapy, ACE Inhibitors For Other Indications
4) By Immune Checkpoint Inhibitors: PD-1 Or PD-L1 Inhibitors, CTLA-4 Inhibitors
What Market Trends Are Affecting The Next Generation Immunotherapies Market?
Leading companies in the next-generation immunotherapies market are concentrating on developing innovative treatments, such as CAR T-cell therapy, to address cancers, autoimmune diseases, and infectious diseases. CAR T-cell therapy is an immunotherapy technique where a patient’s T cells, a type of immune cell, are genetically modified to express chimeric antigen receptors (CARs). For instance, in January 2025, Immuneel Therapeutics Private Limited, an India-based cell and gene therapy startup, introduced Qartemi, India’s first CAR T-cell therapy. This therapy, aimed at adult B-cell non-Hodgkin lymphoma, functions by genetically altering a patient’s immune cells to target and eradicate cancer cells, providing a highly effective and personalized treatment option. It offers new hope to patients for whom conventional therapies have failed, with the added benefit of being more affordable than similar global alternatives.
Who Are The Companies Operating Across The Next Generation Immunotherapies Market Value Chain?
Major companies operating in the next generation immunotherapies market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Incyte Corporation, BioNTech SE, Xencor Inc., Fate Therapeutics Inc., Immatics N.V., Atara Biotherapeutics Inc., Menarini Group, Alpine Immune Sciences Inc., Mereo Biopharma Group plc, Immunomic Therapeutics Inc., Indaptus Therapeutics Inc.
Get The Full Next Generation Immunotherapies Market Report:
Which Region Is The Top Contributor To The Next Generation Immunotherapies Market By Share?
North America was the largest region in the next-generation immunotherapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation immunotherapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Next Generation Immunotherapies Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Next Generation Immunotherapies Market 2026, By The Business Research Company
Next Generation Gynecological Cancer Diagnostics Market Report 2026
Breast Cancer Diagnostics Market Report
https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report
Oncology Companion Diagnostics Market Report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model